慢性粒细胞性白血病P16基因表达及临床意义

Clinical Significance and Expression of P16 in Chronic Myelogenous Leukemia

目的检测细胞周期调控因子P16在慢性粒细胞性白血病(CML)患者中的表达,探讨P16在CML中的作用机制及临床意义.方法采用荧光实时定量PCR方法检测18例CML和16例良性血液病为对照组P16的表达,分析P16在CML中有无异常表达及其表达与病情进展和预后的关系.结果CML患者P16的表达水平低于对照组,差异有统计学意义(P<0.05).加速期/急变期P16的表达水平明显低于慢性期、对照组,差异均有统计学意义(P<0.05);慢性期P16基因表达的水平低于对照组,差异无统计学意义(P>0.05).结论P16在CML中的表达水平普遍低于对照组,提示P16在CML中可能有抑癌基因的作用,其表达水平与CML患者的病情进展程度及预后有关.

Objective To examine the expression levels of P16 in the patients with chronic myelogenous leukemia （CML）, and evaluate the pathogenesis and clinical significance of P16 in CML. Methods The real-time quantitative polymerase chain reaction（RQ-PCR） was performed to detect the expression levels of P16 in the bone marrow samples of 18 patients with CML, and 16 samples of benign hemopoietic patients. The relationship between the expression levels of P16 and the progression and prognosis of patients with CML were analyzed. Results The level of P16 was apparently lower expressed in 18 patients with CML than the control group, there was significant difference between patiens with CML and control group （P 〉 0.05 ）. The levels of P16 was apparently lower expressed in accelerated phase/blast crisis phase than in chronic phase and control group （P 〈 0.05 ）. The levels of P16 was lower expressed in chronic phase than the control group （P〉 0.05）. Conclusion P16 has low expression in CML, the roles of P16 in CML may be an anti-oncogene, and the expression level is correlated with the progression and prognosis of patients with CML.